linjc16/ctgov huggingface dataset:
The Effect of Treatment Zone Decentration on Axial Length Elongation After Orthokeratology

Study Overview
=================
Brief Summary
-----------------
Orthokeratology lens is an effective method for myopia control. This study analyzed the effects of treatment zone decentration on axial length elongation in adolescents with orthokeratology lens.

Detailed Description
-----------------
Orthokeratology lens is an effective method for myopia control. This study aimed to investigate the effects of treatment zone decentration on axial length elongation in adolescents with orthokeratology lens in 1 year. Other factors that may affect axial growth were also analyzed.

Official Title
-----------------
The Effect of Treatment Zone Decentration on Axial Length Elongation After Orthokeratology

Conditions
-----------------
Myopia, Orthokeratology

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from 8 to 15years spherical equivalent(SE) was range from -1.00D to -5.00D conform to the standard of wearing orthokeratology lens Exclusion Criteria: ocular diseases and systemic diseases stop wearing for ≥7 days for any reason during the follow-up period keratoconjunctival complications, glare, diplopia, or any other symptoms during follow-up

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change of axial length | The axial length was measured by IOL-Master 500, its expressed in mm | The change of baseline、6 months and 12months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the decentration magnitudes of the treatment zone | The value of decentration magnitudes was obtained and calculated from a corneal topography | up to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myopia, Orthokeratology, Axial length, Decentration
A Population-based Investigation of Related Factors of Birth Weight in China

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish Chinese neonatal network to investigate current situation of neonatal birth weight and related factors. We investigated the risk factors such as sex, gestational age, region, nation, altitude, place of residence, maternal occupation, education level of mother, maternal age, maternal pregnancy diseases and multiple births.

Conditions
-----------------
Risk Factors, Birth Weight

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: live births Gestational age between 24 weeks and 43 weeks Exclusion Criteria: Major malformation Physical deformity Fetal edema Body mass diagnosed in prenatal ultrasound Acute blood loss during delivery

Ages Eligible for Study
-----------------
Maximum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| birth weight |  | 2 year |
Clinical Trial of Hysteroscopy in Postmenopausal Women to Compare Techniques

Study Overview
=================
Brief Summary
-----------------
Nowadays,hysteroscopy is a golden standard procedure to describe the morphology of uterine cavity and investigate of abnormal uterine bleeding . The success of the procedure is based on the distension of the cavity . It can cause pain and discomfort and sometimes the procedure fails. . There are two techniques to make the procedure , one with gas and the other with saline solution. Objective: to compare two techniques concerning pain , procedure duration and image quality

Detailed Description
-----------------
The objective of this study is to compare two techniques in office hysteroscopy.In this clinical trial postmenopausal women will undergo a diagnostic hysteroscopy using carbon dioxide or saline solution to uterine cavity distension. There will be two groups of 70 women each. The objective is to determine which technique provides better image,time of procedure and less discomfort.

Official Title
-----------------
Phase 1 Study of Two Techniques in Hysteroscopy That Compare Carbon Dioxide Versus Saline Solution

Conditions
-----------------
Postmenopausal Women, Hysteroscopy

Intervention / Treatment
-----------------
* Procedure: procedure hysteroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women post-menopausal with abnormal uterine bleeding, ultrasound with thick endometrial distorted Exclusion Criteria: Women with uterine malformations Women with mental retardation Women underwent pelvic radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: procedure hysteroscopy|office hysteroscopy with gas or saline solution|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the comfort in office hysteroscopy | 140 women will undergo office hysteroscopy to evaluate pain, time of the procedure and image quality using two techniques one with gas and the other with saline solution. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hysteroscopy, saline solution, carbon dioxide, compare two techniques in office hysteroscopy co2 and saline solution
Assessment of Compliance With Antihypertensive Telmisartan Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to asses the efficacy and safety of Telmisartan depending on the use of an electronic therapy monitoring device (HelpingHand) in a real life setting and to asses patients compliance to the therapy with Telmisartan in relation to use of electronic therapy monitoring device.

Official Title
-----------------
A Non-Interventional, Post-Marketing Surveillance, Phase IV Study to Assess Compliance With Antihypertensive Telmisartan Therapy

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 Untreated or ineffectively treated arterial hypertension Exclusion Criteria: Cholestatic disorders and severe hepatic failure Allergy to Telmisartan Pregnancy and lactation period Unwillingness to participate in the study Inability to use the drug reminder device Unwillingness to use the drug reminder device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)<br>* Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy and safety of the treatment with telmisartan reported by the physician with regard to usage the HelpingHand device |  | At all four planned control visits. (Approx. interval between visits 3 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance with the treatment calculated on the basis of by HelpingHand and patients questionnaires |  | At all four planned control visits. (Approx. interval between visits 3 months) |
GOLIATH - General Or Local Anaestesia in Intra Arterial THerapy

Study Overview
=================
Brief Summary
-----------------
Patients suffering a stroke with a large vessel occlusion is often treated intra veneous thrombolyse and on top of that also intra arterial therapy. It is unknown what form of anaestesia is best during intra arterial therapy. The investigators will randomize these patients between general anaestesia and local anaestesia. Outcome will be growth of the ischemic lesion as judged on an MRI scan.

Official Title
-----------------
Anaesthetic Strategy During Endovascular Therapy: General Anaesthesia or Conscious Sedation ?

Conditions
-----------------
Stroke, Anesthesia, Cerebral Revascularization

Intervention / Treatment
-----------------
* Procedure: Local anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: NIHSS>10 mRS=<2 groin puncture<6hours from stroke onset occlusion of ICA, ICA-T, M1, M2 Exclusion Criteria: MRI contraindications GCS<9 intubated prior to arrival posterior circulation stroke allergy to anestetics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: General Anesthesia<br>The patients, who will receive general anesthesia during intervention | |
| Experimental: Local Anesthesia<br>The patients, who will receive local anesthesia/conscious sedation during intervention | Procedure: Local anesthesia<br>* Conscious sedation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth of DWI lesion |  | 48-72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from arrival to groin puncture and recanalization |  | 1-2 hours | 
| Blood pressure during intervention |  | 1-2 hours | 
| Modified Rankin Score |  | 90 days |
The Diagnosis and Mechanism of Pleural Effusion

Study Overview
=================
Brief Summary
-----------------
The diagnosis, treatment and mechanism of pleural diseases

Detailed Description
-----------------
The diagnosis and treatment of benign and malignant pleural effusions, the mechanisms of pleural diseases

Official Title
-----------------
The Diagnosis and Mechanism of Pleural Effusion

Conditions
-----------------
Pleural Diseases

Intervention / Treatment
-----------------
* Other: Collection of pleural effusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with pleural effusion, who has not been treated Exclusion Criteria: Patients with pleural effusion, who has already been treated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental group<br>patients with malignant pleural effusion | Other: Collection of pleural effusion<br>* Detection of pleural effusion<br>|
| control group<br>patients with benign pleural effusion | Other: Collection of pleural effusion<br>* Detection of pleural effusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival | the percentage of people in a group who are alive after a year for malignant pleural effusion | 1 years |
Markers of Defective Membrane Remodelling in Scott-like Syndromes

Study Overview
=================
Brief Summary
-----------------
Purpose: Identification of the gene(s) involved in plasma membrane remodelling. Identification of the circulating markers affected by the defective membrane remodelling in a collection of families with unexplained provoked hemorrhages and evaluation of their prognosis value in the assessment of the hemostatic cellular response.Hypothesis: Scott syndrome is rare a familial disorder characterized by provoked haemorrages in homozygous-type patients due to isolated membrane remodelling deficiency. Membrane remodelling is necessary for cellular hemostatic responses.

Official Title
-----------------
Defect in Cell Stimulation and Unexplained hemorrhagesMarkers Related to Membrane Remodelling in the Prognosis Scott-like Syndormes

Conditions
-----------------
Unexplained Isolated Provoked Hemorrhages, Familial Bleeding Disorder, Scott Syndrome

Intervention / Treatment
-----------------
* Other: Blood withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with unexplained provoked hemorrhages (surgery, tooth extraction, birth …), and associated with reduced prothrombin consomption (residual prothrombine in serum > à 5%). Family members of the patients defined above, with or without unexplained hemorrhages (symptomatic or not). Patient's approval based on detailed information given by the pratician Exclusion Criteria: Patients with primary hemostasis defect or defective blood coagulation factor(s) possibly explaining the bleeding disorder. Anémia, patients known to be affected by Factor V New York . Patients enrolled in a previous clinical study, the exclusion period of which is not yet completed. - Collaboration to the study rejected by the patient Patients that are not registered for medical care social insurance.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients with unexplained bleeding disorder | Other: Blood withdrawal<br>* Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.<br>|
| 2<br>healthy volunteers | Other: Blood withdrawal<br>* Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Defective gene(s) in plasma membrane remodelling., Scott syndrome,, Reduced prothrombin consumption,, Circulating biomakers of scott syndrome
The Effect of Hemodialysis on Hearing

Study Overview
=================
Brief Summary
-----------------
The inner ear contains transporters that are responsible for maintaining a strict homeostatic environment, necessary for transmission and transduction of sound waves. Hemodialysis affects the body's composition including the aspects regulated by these transporters (pH, osmolarity, Na, K). We wish to observe if hemodialysis affects hearing, and if so, by which parameters.

Official Title
-----------------
The Effect of Hemodialysis on Hearing in Hemodialysis Patients

Conditions
-----------------
Hearing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients on hemodialysis Exclusion Criteria: known hearing defect

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemodialysis, Hearing, Hemodialysis patients
Nerve Growth Factor for the Treatment of Cornea Disease

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.

Detailed Description
-----------------
This is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the treatment of LSCD with associated neurotrophic keratopathy. Patient diagnosed with LSCD with neurotrophic cornea who have failed conventional treatment such as artificial tears are enrolled in the study after a 2 week washout period. Patient are then treated with cenegermin-bkbj over an 8 week period.

Official Title
-----------------
Observational Study of Cenegermin-bkbj in the Treatment of Limbal Stem Cell Deficiency Associated With Neurotrophic Keratopathy

Conditions
-----------------
Neurotrophic Keratitis

Intervention / Treatment
-----------------
* Drug: Cenegermin-Bkbj


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with LSCD and neurotrophic cornea confirmed by testing with Cochet-Bonnet aesthesiometer Exclusion Criteria: Active ocular infection Anticipated need for bandage contact lens, amniotic membrane graft, or tarsorrhaphy during the study period Unable to discontinue the use of contact lens Visual acuity worse than 20/200 in the better eye

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Size of abnormal epithelium | Change in size of abnormal epithelium compared to baseline | Baseline, week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with resolution of epithelial defect if present prior to treatment | Number of patients with resolution of epithelial defect if present prior to treatment (Stage 2) Mackie Classification of neurotrophic cornea at time of enrollment. | Baseline, week 8 | 
| Cornea sensation | Cornea sensation measured with Cochet-Bonnet aesthesiometer after treatment compared to screening visit. | Baseline, week 8 |
Hypersensitivity Reactions During Anesthesia

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to study the natural history of allergic reactions during anesthesia and its causes and risk factors.

Official Title
-----------------
Hypersensitivity Reactions During Anesthesia: A Single Center Study

Conditions
-----------------
Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over age 18 undergoing surgery at Mayo Clinic Florida Exclusion Criteria: Minors under age 18 Unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence. | Current estimates are between 1:400 to 1:10,000 surgeries mostly based on retrospective reviews. We will report incidence based on numbers of event/number of surgeries | 2-3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors | Risk factors; including female gender, prior reactions during surgery, sensitization to a previous agent used during surgery | 2-3 years |
Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

Study Overview
=================
Brief Summary
-----------------
To follow the effectiveness of Sorbion Dressing in the treatment of highly exuding venous leg ulcers.

Detailed Description
-----------------
Wounds will be assessed for inclusion into the study, digital images of the wound will be taken, wound will be cleansed, a sorbion dressing will be placed on wound and a cover dressing with be used to keep in place. The wound will be assessed and a dressing change will take place weekly for 4 weeks. At the final visit a final wound evaluation will be done.

Official Title
-----------------
Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

Conditions
-----------------
Venous Wound Ulcers

Intervention / Treatment
-----------------
* Device: Sorbion Dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: venous leg ulcer Exclusion Criteria: pregnant females

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sorbion dressing to venous leg ulcer<br>any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed | Device: Sorbion Dressing<br>* Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks<br>* Other names: Sorbion Sachet sorbion sana;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound Size | decreased wound bed measured in centimeters | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound Maceration | visual assessment of decreased wound maceration | 4 weeks | 
| Wound Necrosis | visual assessment of decreased wound necrosis | 4 weeks |